News and Updates

• 05/01/2013 -
• Sunshine Biopharma Narrows Kilogram Manufacturing Options For Adva-27a Breast Cancer Drug Candidate to Three Suppliers

• 04/09/2013 -
• Sunshine Biopharma HMEC Study Indicates Novel Anticancer Compound Adva-27a Non-Toxic at High Concentrations

• 03/14/2013 -
• Sunshine Biopharma Commences Negotiations with Contract Manufacturing Organizations for Production of its Multidrug-Resistant Breast Cancer Drug, Adva-27a

• 02/26/2013 -
• Sunshine Biopharma Reports on IND Research for its Novel Breast Cancer Drug Candidate, Adva-27a

• 01/15/2013 -
• Advanomics Corporation, The Parent Company of Sunshine Biopharma, Files A New Patent Application For Its Multidrug Resistance Adva-27a Anticancer Compound

• 12/10/2012 -
• Sunshine Biopharma Completes Another IND-Enabling Study: Adva-27a Is Found To Be Effective Against Multidrug Resistant Uterine Cancer Cells

• 12/04/2012 -
• Sunshine Biopharma Completes Six IND-Enabling Studies for its Anticancer Compound, Adva-27a

• 11/27/2012 -
• Advanomics Corporation, The Parent Company of Sunshine Biopharma, Completes Acquisition of Adva-27a Patents ( PDF | DOC )

• 11/13/2012 -
• Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a

• 10/09/2012 -
• Sunshine Biopharma Receives Scale-Up Manufacturing Protocol For Its Lead Anti-Cancer Compound, Adva-27a

• 09/25/2012 -
• Sunshine Biopharma’s Adva-27a Preclinical Research Results to be Published in October Issue of ANTICANCER RESEARCH ( DOC )

• 09/20/2012 -
• Breast Cancer News: Geron Drug Fails, Herceptin® May Increase Heart Problems, Sunshine Biopharma Heading for Clinical Trials ( PDF | DOC )

• 09/13/2012 -
• Sunshine Biopharma Advances to Next Phase of Drug Development with Lead Anti-Cancer Compound, ADva-27a ( PDF DOC )

• 09/04/2012 -
• Sunshine Biopharma Takes Delivery of Newly Manufactured Batch of Adva-27a and Proceeds to Conducting Biological Verification of the Compound's Anti-Cancer Activity

• 08/15/2012 -
• Sunshine Biopharama Announces Submission of an Adva-27a Manuscript for Publication in a Peer-Reviewed Scientific Journal

• 08/03/2012 -
• BUYINS.NET Issues Sunshine Biopharma Squeeze Trigger Report

• 07/30/2012 -
• Sunshine Biopharma, Inc. (OTCBB: SBFM) – Targeting the Challenge of Multidrug Resistance in Breast and Lung Cancer by Developing Adva-27a

• 07/24/2012 -
• Biotech Investor Alert: CFO of Sunshine Biopharma (OTCBB: SBFM) Expands on Significance of Recent Manufacturing News of Lead Anti-Cancer Compound Adva-27a

• 07/19/2012 -
• Sunshine Biopharma Engages Beta Pharma Canada For Manufacturing of an Initial Batch of Adva-27a

• 07/16/2012 -
• Biotech Investor Q&A with Roche (SIX: RO, ROG; OTCQX: RHHBY) and Sunshine Biopharma (OTCBB: SBFM) Discussing Lead Cancer Products

• 07/11/2012 -
• Biopharma Stocks Reporting on Lung Cancer Developments: Sunshine Biopharma (OTCBB: SBFM), OncoGenex (NASDAQ: OGXI)

• 07/09/2012 -
• Targeting Aggressive Forms of Cancer: Sunshine Biopharma (OTCBB:SBFM) and Roche (SIX: RO, ROG; OTCQX: RHHBY)

• 07/02/2012 -
• Biotech Investor Q&A with CFO of Sunshine Biopharma (OTCBB:SBFM) Discussing its Lead Compound - Adva-27a for Aggressive Forms of Cancer

• 06/26/2012 -
• Sunshine Biopharma's Adva-27a Found to be Effective at Killing Multidrug Resistant Lung Cancer Cells

• 05/22/2012 -
• Pharmacokinetics Parameters of Sunshine Biopharma's Lead Anti-Cancer Compound Exceed Expectations

• 04/09/2012 -
• Sunshine Biopharma Announces Issuance of Notice of Allowance for the Patent Application Covering its Adva-27a Anti-Cancer Compound

• 03/26/2012 -
• Sunshine Biopharma and Binghamton University to Present New Data at the Upcoming American Association for Cancer Research Meeting in Chicago

• 11/28/2011 -
• Avastin Ousted by FDA for Breast Cancer, Sunshine Biopharma Gears-Up for Clinicals

• 11/15/2011 -
• Sunshine Biopharma's Announces Successful Completion of Preclinical Studies for Adva-27a, The Company's Lead Anti-Cancer Compound

• 10/05/2011 -
• Sunshine Biopharma's Anti-Cancer Compound, Adva-27a, found to be a Topoisomerase II Inhibitor

• 08/30/2011 -
• Clearance of Sunshine Biopharma's Anti-Cancer Compound, Adva-27a, Does Not Involve a Toxic Intermediate

• 07/27/2011 -
• Sunshine Biopharma Looking to Mimic Roche's Billion Dollar Cancer Drug Success

• 07/25/2011 -
• Sunshine Biopharma's Lead Anti-tumor Compound, Adva-27a, is cleared via a cytochrome P450-Independent Mechanism

• 07/11/2011 -
• Sunshine Biopharma’s Adva-27a is 16-times more effective at killing multidrug resistant breast cancer cells

• 06/27/2011 -
• Sunshine Biopharma's Lead Anti-Cancer Compound, Adva-27a, performs exceptionally well in human microsome stability assays

• 06/17/2011 -
• Sunshine Biopharma enters into clinical trials agreement with the Jewish General Hospital in Montreal, Canada

• 04/26/2011 -
• Sunshine Biopharma’s CEO Does Live Interview on ChartPoppers.com

• 04/01/2011 -
• Sunshine Biopharma to appear at American Association for Cancer Research Meeting

• 03/04/2011 -
• CEO CFO Interviews Dr. Steve N. Slilaty

• 02/25/2011 -
• Interview with Central NY Business Journal

• 01/26/2011 -
• FOX 40 WICZ.COM Interview of Binghamton University on Sunshine BioPharma Part 1

• 01/21/2011 -
• SUNSHINE BIOPHARMA AND BINGHAMTON UNIVERSITY (STATE UNIVERSITY OF NEW YORK) ENTER INTO RESEARCH AGREEMENT